Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel, Dmitry I. Gabrilovich
Douglas Marvel, Dmitry I. Gabrilovich
Published July 13, 2015
Citation Information: J Clin Invest. 2015;125(9):3356-3364. https://doi.org/10.1172/JCI80005.
View: Text | PDF
Review Series

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

  • Text
  • PDF
Abstract

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.

Authors

Douglas Marvel, Dmitry I. Gabrilovich

×

Figure 2

Potential role of immature myeloid cells and MDSCs in the regulation of tumor development and progression.

Options: View larger image (or click on image) Download as PowerPoint
Potential role of immature myeloid cells and MDSCs in the regulation of ...
(A) Immature myeloid cells (IMCs) with the typical phenotype of MDSCs are produced in response to inflammatory stimuli. However, these cells often lack immunosuppressive activity. They contribute to tumorigenesis by recruiting proinflammatory CD4+ T cells that promote epithelial cell proliferation. (B) Tumor development is associated with the expansion of cells with acquired immunosuppressive activity (MDSCs). These cells also promote tumor cell invasion and angiogenesis and neutralize tumor cell senescence. (C) In metastatic tumors, MDSCs, in addition to promoting tumor cell invasion and angiogenesis, can support EMT and differentiation of osteoclasts supporting bone resorption.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts